Pilot Study of Low‐Dose Interleukin‐2, Pegylated Interferon–α2b, and Ribavirin for the Treatment of Hepatitis C Virus Infection in Patients with HIV Infection
- 1 March 2005
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 191 (5) , 686-693
- https://doi.org/10.1086/427812
Abstract
BackgroundPatients infected with hepatitis C virus (HCV) and human immunodeficiency virus have a diminished HCV virologic response to standard interferon (IFN)–based therapies. We explored the strategy of initial immunostimulatory therapy with interleukin (IL)–2, followed by the addition of specific anti-HCV therapy, as a possible synergistic approach to treatmentKeywords
This publication has 0 references indexed in Scilit: